Efficacy and toxicity of immune checkpoint inhibitors combination therapy for advanced renal cell carcinoma: a systematic review and network meta-analysis. | 2024 | Frontiers in Immunology |
Comparing efficacy and safety of first-line treatment of metastatic renal cell carcinoma: A Bayesian network meta-regression analysis. | 2023 | Frontiers in Oncology |
First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis. | 2023 | The Cochrane Database of Systematic Reviews |
Efficacy and safety of checkpoint inhibitors in clear cell renal cell carcinoma: a systematic review of clinical trials. | 2023 | Hematology/Oncology and Stem Cell Therapy |
Optimizing targeted drug selection in combination therapy for patients with advanced or metastatic renal cell carcinoma: a systematic review and network meta‐analysis of safety. | 2023 | Cancer Medicine |
A systematic review to summarize treatment patterns, guidelines, and characteristics of patients with renal cell carcinoma in the Asia-Pacific region. | 2023 | Expert Review of Anticancer Therapy |
Clinical outcomes and adverse events after first-line treatment in metastatic renal cell carcinoma: a systematic review and network meta-analysis. | 2022 | The Journal of Urology |
Second-line treatments for advanced hepatocellular carcinoma: a systematic review and Bayesian network meta analysis. | 2022 | Clinical and Experimental Medicine |
Efficacy and safety of first-line systemic therapy for metastatic renal cell carcinoma: a systematic review and network meta-analysis. | 2022 | European Association of Urology |
First-line therapy for elderly patients with advanced renal cell carcinoma in the immuno-oncology era: a network meta-analysis | 2022 | Cancer Immunology, Immuno therapy |
Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review | 2022 | Therapeutic Advances in Medical Oncology |
Systemic therapy for metastatic renal cell carcinoma in the first‑line setting: a systematic review and network meta‑analysis. | 2021 | Cancer Immunology, Immunotherapy |
A living, interactive systematic review and network meta-analysis of first-line treatment of metastatic renal cell carcinoma. | 2021 | European Association of Urology |
Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: a systematic review and meta-analysis. | 2021 | European Journal of Cancer |
A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma. | 2021 | Journal of Clinical Pharmacy and Therapeutics |
Targeted therapy for metastatic renal cell carcinoma. | 2020 | Cochrane Database of Systematic Reviews |
What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis. | 2020 | BMJ Open |
First-line treatments for advanced renal cell carcinoma with immune checkpoint inhibitors: systematic review, network meta-analysis and cost-effectiveness analysis. | 2020 | Therapeutic Advances in Medical Oncology |
Comparative efficacy of first-line immune-based combination therapies in metastatic renal cell carcinoma: a systematic review and network meta-analysis. | 2020 | Cancers |
The clinical significance of routine risk categorization in metastatic renal cell carcinoma and its impact on treatment decision-making: a systematic review. | 2020 | Future Oncology |
First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. | 2019 | European Urology Oncology |
Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: A Bayesian network analysis. | 2019 | EBioMedicine |
Targeted therapies for previously treated advanced or metastatic renal cell carcinoma: systematic review and network meta-analysis | 2019 | BMJ Open |